Holen Sie sich die Stockscreener-App
14.01
0.14%
0.02
Schlusskurs vom Vortag:
$13.99
Offen:
$14.24
24-Stunden-Volumen:
1.14M
Relative Volume:
0.71
Marktkapitalisierung:
$1.43B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-294.51M
KGV:
-3.9354
EPS:
-3.56
Netto-Cashflow:
$-244.42M
1W Leistung:
+0.72%
1M Leistung:
-3.71%
6M Leistung:
-70.22%
1J Leistung:
-37.87%
1-Tages-Spanne:
$13.80
$14.54
1-Wochen-Bereich:
$13.59
$14.54
52-Wochen-Spanne:
$13.07
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
14.01 | 1.43B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Myotonic Dystrophy Pipeline Analysis 2024: FDA Approvals - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock - Investing.com India
Dyne Therapeutics Officer Sells Shares to Satisfy Tax Obligations - TradingView
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(DYN) Technical Data - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Sets New 52-Week LowWhat's Next? - MarketBeat
abrdn plc Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics to Present Key Data from DELIVER and ACHIEVE Clinical Trials at 2025 MDA Conference - Nasdaq
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific - The Bakersfield Californian
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - GlobeNewswire
Major Clinical Data Alert: Dyne's DMD and DM1 Trial Results Set for Exclusive MDA Conference Reveal - StockTitan
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) - Yahoo Finance
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5%Here's What Happened - MarketBeat
abrdn plc Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics To Present At Oppenheimer Healthcare Conference; Webcast At 4:00 PM ET - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Dyne Therapeutics (NASDAQ:DYN) Trading Up 7%Time to Buy? - MarketBeat
Dyne Therapeutics Shares Rise Premarket as DMD Study Gets FDA Nod -July 05, 2022 at 08:18 am EDT - Marketscreener.com
Jennison Associates LLC Sells 135,037 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Insider Monkey
DYN Stock Sees Surge of Approximately 15.81% in Last Five Days - Knox Daily
Learn to Evaluate (DYN) using the Charts - Stock Traders Daily
10 Best Rebound Stocks To Invest In Now - Insider Monkey
Investor’s Delight: Dyne Therapeutics Inc (DYN) Closes Weak at 13.87, Down -2.46 - The Dwinnex
Dyne Therapeutics Inc’s results are impressive - US Post News
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
DYN (Dyne Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Dyne Therapeutics Reveals Latest Developments at Major Healthcare ConferenceKey Updates Coming - StockTitan
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Recent Analysts’ Ratings Changes for Dyne Therapeutics (DYN) - Defense World
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround - MSN
Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Guggenheim - Defense World
Dyne Therapeutics' (DYN) Buy Rating Reiterated at Guggenheim - MarketBeat
(DYN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week LowTime to Sell? - MarketBeat
Dyne Therapeutics: Moving Forward On 2 Key Fronts - Seeking Alpha
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):